Systemic and Local Inflammatory Biomarkers in the Treatment of Refractory Diabetic Macular Edema

Sponsor
Saglik Bilimleri Universitesi
Study ID
NCT06179030
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

  • serum samples — DIAGNOSTIC_TEST
    The serum samples were taken from the patients at the 3rd month (switch point)
  • dexamethasone implant versus ranibizumab — DRUG
    dexamethasone implant versus ranibizumab will be studied as a secondary outcome

Study Details

The current study aims to investigate the relationship between systemic inflammatory biomarkers and local inflammatory biomarkers on OCT in patients with treatment resistant diabetic macular edema(DME) and further explore the associations with treatment outcomes.

Key Dates

First listed
Dec 21, 2023
Start date
May 1, 2022
Status verified
Dec 2023
Primary completion
Oct 17, 2023
Completion
Oct 17, 2023

Study Design

Enrollment
80 participants (actual)

Arms

  • Arm: Group 1
    switched from bevacizumab to ranibizumab 0.5
  • Arm: Group 2
    switched from bevacizumab to dexamethasone implant

Primary Outcome Measure

systemic inflammatory biomarkes correlates with OCT biomarkers and higher in poor responders [ Time Frame: 6 months ]

Related Studies